Women between 18 and 35 can help researchers understand the effects of some medications for postmenopausal osteoporosis and hasten development of more effective treatments for the condition.
Researchers at UC and six other sites across the country are studying how bone markers change during a normal menstrual cycle in premenopausal women.
"Bone markers are molecules that can be measured in the blood," says Margery Gass, MD, professor of obstetrics and gynecology at UC and the national principal investigator for the study. "These molecules tell us how much change is happening in the bone.
"Bone is a complex living tissue that constantly renews itself. The body builds and stores bone tissue efficiently until age 30-35. With aging, however, bones begin to break down faster than new bone is formed.
This breakdown, osteoporosis, is more prevalent in women than men. Women have smaller bones to start with, and the loss of estrogen during menopause causes them to lose bone more rapidly for a short time.
"Most people don't realize that bone is a dynamic organ that builds and dissolves in response to the stresses placed on it," says Dr. Gass. "Bone metabolism is also affected by hormones, which fluctuate during a woman's menstrual cycle.
"Synthetic hormones, such as those in birth control pills, also affect bones-in general, they help protect the bone and increase bone density. That's why we want to study the bone markers of women who are not taking oral contraceptives," Dr. Gass says.
According to Dr. Gass, bones have many markers, but researchers are unsure which are the best to measure.
"This study is important," she says, "because if we can isolate which markers best reflect the quality of bone in premenopausal women, we can develop better therapies to treat postmenopausal women who lose more bone than they build."
For more information, call (513) 584-4100 or visit www. researchforwomen.com. Dr. Gass has received honoraria and consulting fees from the study sponsors, Roche Pharmaceuticals.